IPP Bureau
USFDA completes audit of contract manufacturing facility of Jubilant Pharmova Montreal unit
By IPP Bureau - June 19, 2024
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
FDA approves Lenire device by Neuromod for tinnitus treatment option for US veterans
By IPP Bureau - June 19, 2024
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Pfizer reports positive results from Echelon-3 study
By IPP Bureau - June 17, 2024
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Indian medical device industry to touch US$ 50 billion by 2030
By IPP Bureau - June 17, 2024
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary
By IPP Bureau - June 17, 2024
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals
By IPP Bureau - June 17, 2024
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Imfinzi approved in the US for endometrial cancer
By IPP Bureau - June 17, 2024
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Alembic announces USFDA final approval for Icatibant injection
By IPP Bureau - June 17, 2024
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%
By IPP Bureau - June 17, 2024
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
USFDA approves next-gen TKI Augtyro for treatment of solid tumors
By IPP Bureau - June 17, 2024
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Health Minister Nadda aims to attain targeted Health goals in the first 100 days of formation of new government
By IPP Bureau - June 15, 2024
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Fischer Medical Ventures and The Therapy Platform partner for mental healthcare
By IPP Bureau - June 15, 2024
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
By IPP Bureau - June 15, 2024
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Sun Pharma and Moebius Medical present Phase 2b study on MM-II
By IPP Bureau - June 15, 2024
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
